Literature DB >> 12007940

Stereotactically guided conformal radiotherapy for progressive low-grade gliomas of childhood.

Frank H Saran1, Brigitta G Baumert, Vincent S Khoo, Elizabeth J Adams, Maria L Garré, Alan P Warrington, Michael Brada.   

Abstract

PURPOSE: To describe the rationale, technique, and early results of stereotactically guided conformal radiotherapy (SCRT) in the treatment of progressive or inoperable low-grade gliomas (LGGs) of childhood. METHODS AND MATERIALS: Between September 1994 and May 1999, 14 children (median age 6 years, range 5-16) with LGG were treated with SCRT at the Royal Marsden NHS Trust. Tumors were located at the optic chiasm (n = 9), third ventricle (n = 2), hypothalamus, craniocervical junction, and pineal region (each n = 1). Four patients received chemotherapy before SCRT. Immobilization was in a Gill-Thomas-Cosman frame (n = 12) and subsequently in a specially designed pediatric version of the frame (n = 2). Stereotactic coordinates and the tumor were defined by CT scanning with a fiducial system and MRI fusion. The median tumor volume was 19.5 cm(3) (range 7.5-180). The planning target volume was defined as the area of enhancing tumor plus a 5-10-mm margin. The treatment technique consisted of 4 isocentric, noncoplanar, conformal, fixed fields. Treatment was delivered in 30-33 daily fractions to a total dose of 50-55 Gy.
RESULTS: SCRT was well tolerated, with transient hair loss the only acute toxicity. The median follow-up was 33 months (range 2-53). At 6 months after SCRT, 4 of 12 children with neurologic deficits improved and 5 remained stable. Twelve children were available for MRI evaluation. Two had a complete response, 6 a partial response, and 4 stable disease. One child with optic chiasm glioma had local progression at 25 months, and 1 developed diffuse leptomeningeal disease without local progression at 27 months. The 3-year local progression-free survival and overall survival rate after SCRT was 87% and 100%, respectively, compared with 89% and 98% for an historic control treated with conventional RT. New endocrine deficiencies were noted in 2 children after a follow-up of 20 and 23 months.
CONCLUSION: SCRT is a feasible, high-precision technique of RT for children with LGGs for whom RT is considered appropriate. The local control and acute toxicity of SCRT are comparable to a historic control of patients with conventionally delivered RT. The frequency of delayed hypothalamic-pituitary axis dysfunction reflects tumor location adjacent to the hypothalamus and pituitary. Additional follow-up is required to demonstrate that SCRT contributes to a reduction in treatment-related late toxicity, while maintaining the local control achieved with conventionally delivered RT in children with progressive LGGs.

Entities:  

Mesh:

Year:  2002        PMID: 12007940     DOI: 10.1016/s0360-3016(02)02734-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Radiation therapy for pediatric low-grade gliomas: survival and sequelae.

Authors:  Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2010-01       Impact factor: 5.081

Review 2.  Gamma Knife treatment of low-grade gliomas in children.

Authors:  Murat Şakir Ekşi; Baran Yılmaz; Akın Akakın; Zafer Orkun Toktaş; Ahmet Cemil Kaur; Mustafa Kemal Demir; Türker Kılıç
Journal:  Childs Nerv Syst       Date:  2015-07-15       Impact factor: 1.475

3.  Conformal Radiation Therapy for Pediatric Patients with Low-Grade Glioma: Results from the Children's Oncology Group Phase 2 Study ACNS0221.

Authors:  Joel M Cherlow; Dennis W W Shaw; Linda R Margraf; Daniel C Bowers; Jie Huang; Maryam Fouladi; Arzu Onar-Thomas; Tianni Zhou; Ian F Pollack; Amar Gajjar; Sandy K Kessel; Patricia L Cullen; Kevin McMullen; John C Wellons; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-10       Impact factor: 7.038

Review 4.  Treatments for astrocytic tumors in children: current and emerging strategies.

Authors:  Stanislaw R Burzynski
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Retrospective analysis of combination carboplatin and vinblastine for pediatric low-grade glioma.

Authors:  Anandani Nellan; Erin Wright; Kristen Campbell; Kurtis D Davies; Andrew M Donson; Vladimir Amani; Alexis Judd; Molly S Hemenway; Jennifer Raybin; Nicholas K Foreman; Sarah Rush; Kathleen Dorris
Journal:  J Neurooncol       Date:  2020-06-06       Impact factor: 4.130

6.  Radiotherapy in pediatric pilocytic astrocytomas. A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH).

Authors:  K Müller; A Gnekow; F Falkenstein; J Scheiderbauer; I Zwiener; T Pietsch; M Warmuth-Metz; J Voges; G Nikkhah; M Flentje; S E Combs; D Vordermark; M Kocher; R-D Kortmann
Journal:  Strahlenther Onkol       Date:  2013-07-07       Impact factor: 3.621

7.  Gliomas of the pineal region.

Authors:  Salima Magrini; Alberto Feletti; Elisabetta Marton; Pierluigi Longatti
Journal:  J Neurooncol       Date:  2013-07-03       Impact factor: 4.130

Review 8.  Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma.

Authors:  Giorgio Perilongo
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

Review 9.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

10.  The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas.

Authors:  Kavita K Mishra; Dev R Puri; Brian T Missett; Kathleen R Lamborn; Michael D Prados; Mitchel S Berger; Anuradha Banerjee; Nalin Gupta; William M Wara; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2006-02-22       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.